Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
581-600 of 1,782 trials

Pancreatic Exocrine Insufficiency: Creon® Therapy Study

We are exploring how Creon® may help improve nutrition and quality of life for patients with pancreatic exocrine insufficiency after total gastrectomy. The study also looks at weight changes and gastrointestinal symptoms.

Pancreatic Exocrine Insufficiency1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Hormonal Contraceptives: Brain Effects Study

We are comparing two types of hormonal contraceptives to see how they affect brain structure and function. We're also looking at their impact on quality of life and mental health symptoms.

Hormonal Contraception≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsNeurology

Cannabidiol for Refractory Childhood Epilepsy

We are studying whether adding CBD can help children with hard-to-treat epilepsy manage their seizures better. The trial also looks at how this treatment affects the quality of life for patients and their families.

Refractory Epilepsy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Hot Flashes After Breast Cancer: Oxybutynin vs. Venlafaxine

We are studying whether oxybutynin or venlafaxine is more effective in reducing hot flashes in women using endocrine therapy after breast cancer. We will also look at side effects and personal preferences between the two treatments.

Estrogen Receptor Positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

Immunoglobulin A Nephropathy: Ravulizumab Study

We are testing whether ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy. The study will also assess safety and quality of life compared to a placebo.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Severe Systemic Lupus Erythematosus: Belimumab and Rituximab Study

We are investigating whether combining belimumab with rituximab can improve treatment outcomes for people with severe systemic lupus erythematosus. This study will compare this combination to standard treatments to see if it better reduces harmful autoantibodies and improves overall health.

Systemic Lupus Erythematosus>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Self-Administration of Elranatamab for Multiple Myeloma

We are exploring whether patients with multiple myeloma can safely administer Elranatamab at home. The study will assess the feasibility, safety, and impact on quality of life for both patients and their caregivers.

Multiple Myeloma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Acute Myeloid Leukemia: Gilteritinib with Venetoclax and Azacitidine

We are studying a combination of three medications for patients with newly diagnosed acute myeloid leukemia and FLT3 mutations who cannot receive intensive treatment. The goal is to find the best dose that is safe and effective.

Acute Myeloid LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Mpox Vaccination Study: MPOX-VAX

We are studying a vaccine to see how well it prevents Mpox infection and how long the immune response lasts. Participants will also be monitored for other infections to understand overall health impacts.

Mpox Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

Systemic Juvenile Idiopathic Arthritis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Isatuximab for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

We are studying whether Isatuximab can safely help adults with relapsed or refractory T-cell acute lymphoblastic leukemia achieve remission. This trial looks at its effects alone and with other chemotherapy drugs.

T-cell Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Scabies Treatment: Comparing Permethrin Creams

We are testing whether a new 10% permethrin cream works better than the standard 5% cream for treating scabies. We will also look at the safety of the new cream.

Scabies>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious Diseases

Methylphenidate for Cancer-Related Fatigue in Young Brain Tumor Survivors

We are studying whether methylphenidate can help reduce fatigue in patients who were treated for brain tumors during childhood or adolescence. Additionally, we will look at its effects on sleep, cognitive function, and quality of life.

Cancer-related Fatigue after Pediatric Brain Tumor Treatment3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementOncologyPediatrics

Quizartinib for Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

We are studying whether quizartinib, combined with chemotherapy, can improve survival in adults with newly diagnosed FLT3-ITD negative AML compared to a placebo. This trial aims to assess its effectiveness and safety.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementOncology

Colchicine for Angina in Microvascular Disease

We are studying whether colchicine can improve blood flow and reduce symptoms in patients with angina caused by coronary microvascular dysfunction. This research may help us understand how to better treat this condition.

Cardiovascular Disease (CMD)>2 yearsEfficacy phase (II)Standard MedicinesCardiology

Pompe Disease: Enzyme Replacement Therapy Study

We are examining how a new enzyme replacement therapy affects muscle glycogen in people with Pompe disease who have not yet received treatment. This research may help improve future therapies for this condition.

Pompe's Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyHematologyNeurology

Levosimendan for Heart Support During ECMO Weaning

We are studying whether Levosimendan can improve heart function in patients being weaned from ECMO. This may help reduce complications and support recovery during this critical period.

Cardiogenic ShockEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Eosinophilic Granulomatosis with Polyangiitis: Mepolizumab Treatment

We are studying how mepolizumab affects the nasal microbiome and immune response in patients with eGPA. This research may help understand its impact on local inflammation in the ENT area.

Eosinophilic Granulomatosis with Polyangiitis (eGPA)>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOtolaryngology

Acute Myeloid Leukemia: Vyxeos and Clofarabine Study

We are testing a new combination treatment for children with relapsed or refractory AML to find the best dose and evaluate its safety. The study aims to see if this treatment can help achieve remission and support future stem cell transplants.

Acute Myeloid LeukemiaSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Dupilumab for Chronic Rhinosinusitis with Nasal Polyps

We are studying how dupilumab affects ear symptoms and hearing in patients with chronic rhinosinusitis and eosinophilic otitis media. This research aims to improve understanding of treatment benefits for these conditions.

Chronic Rhinosinusitis with Nasal PolypsEosinophilic Otitis Media>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology